Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16516537 | 0.77 | IDO1 (0.41) | HPGDALDH1A1KDM4EIDO1HCAR3 | |
| SCHEMBL16506185 | 0.77 | PTGER4 (0.46) | PTGER4ALDH1A1IRAK4MAP2K3MAPK14 | |
| SCHEMBL16505577 | 0.76 | IDO1 (0.40) | HPGDALDH1A1KDM4EIDO1HCAR3 | |
| SCHEMBL16505728 | 0.76 | PTGER4 (0.40) | PTGER4ALDH1A1IRAK4IDO1HCAR3 | |
| SCHEMBL16505287 | 0.75 | MAP2K3 (0.49) | MAP2K3KDM4EIDO1GLA | |
| SCHEMBL16506229 | 0.74 | PIM1 (0.35) | MAP2K1ALDH1A1MAP2K3MAPK14 | |
| SCHEMBL16506089 | 0.74 | HCAR3 (0.41) | PTGER4HPGDALDH1A1KDM4EHCAR3 | |
| SCHEMBL16517545 | 0.74 | HCAR3 (0.41) | ALDH1A1MAPK14KDM4EHCAR3L3MBTL1 | |
| SCHEMBL16505583 | 0.74 | MAP3K14 (0.59) | — | |
| SCHEMBL16517729 | 0.74 | MAP3K14 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3036229-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | PTGER4 797/4885MAP2K1 3524/4885HPGD 1562/4885 |
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | PTGER4 797/4885MAP2K1 3524/4885HPGD 1562/4885 |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | PTGER4 797/4885MAP2K1 3524/4885HPGD 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.